XPAT® proteins, conditionally activated T-cell engagers engineered to mitigate on-target, off-tumor toxicity for immunotherapy of solid tumors

Fiore Cattaruzza(Sanofi (United States)), Volker Schellenberger(VIR Biotechnology (United States))
Research Square
September 30, 2022
Cited by 1


Related Papers